Return to article

Table 3. Weight, prostate volume and prostate-specific antigen (PSA), testis volume, sexual activity, and bone density data in the 2 treatment groups during 7-methyl-19-nortestosterone (MENT)/testosterone plus etonogestrel treatment^*

Pretreatment   12 Weeks   24 Weeks   36 Weeks   48 Weeks   Recovery   Weight                   T group, kg   80.8 ± 3.8   80.6 ± 3.4   82.2 ± 3.5   83.6 ± 4.1   84.2 ± 3.9   84.1 ± 3.8       MENT group, kg   80.5 ± 3.0   83.0 ± 3.6   81.5 ± 3.7   ...   ...   81.3 ± 3.3   Prostate volume                   T group (mL)   14.7 ± 1.3   ...   16.2 ± 0.9   ...   17.4 ± 0.9   16.9 ± 1.2       MENT group (mL)   16.3 ± 1.4   ...   15.8 ± 2.3   ...   ...   16.4 ± 1.4   PSA                   T group (ng/mL)   0.8 ± 0.1   0.87 ± 0.1   0.84 ± 0.1   0.73 ± 0.1   0.72 ± 0.1   0.68 ± 0.1       MENT group (ng/mL)   1.1 ± 0.2   0.77 ± 0.1   0.74 ± 0.1   ...   ...   0.80 ± 0.1   Testis volume                   T group (mL)   18.6 ± 0.9   13.7 ± 0.9   12.4 ± 0.6   12.6 ± 1.2   11.5 ± 1.1   19.0 ± 0.9       MENT group (mL)   18.1 ± 0.9   12.9 ± 1.0   15.4 ± 1.1   ...   ...   18.6 ± 1.1   Sexual activity                   T group   7.1 ± 0.9   8.7 ± 1.5   7.8 ± 0.9   7.6 ± 1.8   7.4 ± 1.9   7.1 ± 1.2       MENT group   6.9 ± 0.9   5.9 ± 1.3   6.4 ± 1.3   ...   ...   7.9 ± 2.1       T group (g/m2)   1.03 ± 0.02   ...   1.03 ± 0.03   ...   1.08 ± 0.02   1.01 ± 0.06       MENT group (g/m2)   1.05 ± 0.04   ...   1.04 ± 0.04   ...   ...   1.01 ± 0.04   Total hip BMD                   T group (g/m2)   1.08 ± 0.02   ...   1.08 ± 0.02   ...   1.10 ± 0.03   1.08 ± 0.03       MENT group (g/m2)   1.01 ± 0.05   ...   1.01 ± 0.05   ...   ...   1.01 ± 0.05   *Mean ± SEM. MENT group, n = 13; testosterone (T) group, n = 16. BMD indicates bone mineral density   P < .05   P < .01 vs pretreatment. There were no significant differences between the MENT and testosterone groups in any of these variables

Return to article